Genetic studies have identified common mutations in melanoma, including cyclin-dependent kinase inhibitor 2A (CDKN2A), neuroblastoma rat sarcoma viral oncogene homolog (NRAS), phosphatase and tensin homolog (PTEN), and BRAF, with the latter being the most frequent oncogenic mutation. This evidence concerns the gene NRAS and melanoma.